These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33259635)

  • 1. Updating concepts on atherosclerotic inflammation: From pathophysiology to treatment.
    Ministrini S; Carbone F; Montecucco F
    Eur J Clin Invest; 2021 May; 51(5):e13467. PubMed ID: 33259635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
    Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
    Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions.
    Raggi P; Genest J; Giles JT; Rayner KJ; Dwivedi G; Beanlands RS; Gupta M
    Atherosclerosis; 2018 Sep; 276():98-108. PubMed ID: 30055326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory Response During Myocardial Infarction.
    Oliveira JB; Soares AASM; Sposito AC
    Adv Clin Chem; 2018; 84():39-79. PubMed ID: 29478516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.
    Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases.
    Carbone F; Nencioni A; Mach F; Vuilleumier N; Montecucco F
    Thromb Haemost; 2013 May; 109(5):854-68. PubMed ID: 23446994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on selective treatments targeting neutrophilic inflammation in atherogenesis and atherothrombosis.
    Gomes Quinderé AL; Benevides NM; Carbone F; Mach F; Vuilleumier N; Montecucco F
    Thromb Haemost; 2014 Apr; 111(4):634-46. PubMed ID: 24285257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
    Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC
    Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines as therapeutic targets for cardio- and cerebrovascular diseases.
    Liberale L; Ministrini S; Carbone F; Camici GG; Montecucco F
    Basic Res Cardiol; 2021 Mar; 116(1):23. PubMed ID: 33770265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-cytokine therapy for prevention of atherosclerosis.
    Kirichenko TV; Sobenin IA; Nikolic D; Rizzo M; Orekhov AN
    Phytomedicine; 2016 Oct; 23(11):1198-210. PubMed ID: 26781385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation in coronary artery diseases.
    Li JJ
    Chin Med J (Engl); 2011 Nov; 124(21):3568-75. PubMed ID: 22340179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting inflammation to reduce recurrent stroke.
    Zietz A; Gorey S; Kelly PJ; Katan M; McCabe JJ
    Int J Stroke; 2024 Apr; 19(4):379-387. PubMed ID: 37800305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical roles of inflammation in atherosclerosis.
    Moriya J
    J Cardiol; 2019 Jan; 73(1):22-27. PubMed ID: 29907363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities.
    Khambhati J; Engels M; Allard-Ratick M; Sandesara PB; Quyyumi AA; Sperling L
    Atherosclerosis; 2018 Sep; 276():1-9. PubMed ID: 30006321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel anti-inflammatory therapies for the treatment of atherosclerosis.
    Khan R; Spagnoli V; Tardif JC; L'Allier PL
    Atherosclerosis; 2015 Jun; 240(2):497-509. PubMed ID: 25917947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in therapeutic targeting of inflammation in atherosclerosis.
    Hedin U; Matic LP
    J Vasc Surg; 2019 Mar; 69(3):944-951. PubMed ID: 30591299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex as a Biological Variable in Atherosclerosis.
    Man JJ; Beckman JA; Jaffe IZ
    Circ Res; 2020 Apr; 126(9):1297-1319. PubMed ID: 32324497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13.
    Halvorsen B; Smedbakken LM; Michelsen AE; Skjelland M; Bjerkeli V; Sagen EL; Taskén K; Bendz B; Gullestad L; Holm S; Biessen EA; Aukrust P
    Atherosclerosis; 2014 Jun; 234(2):352-9. PubMed ID: 24732574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.